150 related articles for article (PubMed ID: 28336564)
21. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.
Pessetto ZY; Chen B; Alturkmani H; Hyter S; Flynn CA; Baltezor M; Ma Y; Rosenthal HG; Neville KA; Weir SJ; Butte AJ; Godwin AK
Oncotarget; 2017 Jan; 8(3):4079-4095. PubMed ID: 27863422
[TBL] [Abstract][Full Text] [Related]
22. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway.
Dong Y; Liang G; Yuan B; Yang C; Gao R; Zhou X
Tumour Biol; 2015 Mar; 36(3):1477-86. PubMed ID: 25431257
[TBL] [Abstract][Full Text] [Related]
23. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
24. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.
Crompton BD; Carlton AL; Thorner AR; Christie AL; Du J; Calicchio ML; Rivera MN; Fleming MD; Kohl NE; Kung AL; Stegmaier K
Cancer Res; 2013 May; 73(9):2873-83. PubMed ID: 23536552
[TBL] [Abstract][Full Text] [Related]
25. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD
Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901
[TBL] [Abstract][Full Text] [Related]
26. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
Olsen RR; Mary-Sinclair MN; Yin Z; Freeman KW
PLoS One; 2015; 10(1):e0116998. PubMed ID: 25615615
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
28. TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Moritake H; Saito Y; Sawa D; Sameshima N; Yamada A; Kinoshita M; Kamimura S; Konomoto T; Nunoi H
Cancer Med; 2019 Dec; 8(18):7809-7821. PubMed ID: 31692287
[TBL] [Abstract][Full Text] [Related]
29. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
30. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor.
Li S; Wang Q; Qiang Q; Shan H; Shi M; Chen B; Zhao S; Yuan L
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1909-20. PubMed ID: 25773124
[TBL] [Abstract][Full Text] [Related]
31. The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.
Tee AE; Ling D; Nelson C; Atmadibrata B; Dinger ME; Xu N; Mizukami T; Liu PY; Liu B; Cheung B; Pasquier E; Haber M; Norris MD; Suzuki T; Marshall GM; Liu T
Oncotarget; 2014 Apr; 5(7):1793-804. PubMed ID: 24742640
[TBL] [Abstract][Full Text] [Related]
32. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.
Agelopoulos K; Richter GH; Schmidt E; Dirksen U; von Heyking K; Moser B; Klein HU; Kontny U; Dugas M; Poos K; Korsching E; Buch T; Weckesser M; Schulze I; Besoke R; Witten A; Stoll M; Köhler G; Hartmann W; Wardelmann E; Rossig C; Baumhoer D; Jürgens H; Burdach S; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Nov; 21(21):4935-46. PubMed ID: 26179511
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
34. Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.
Black M; Ghasemi F; Sun RX; Stecho W; Datti A; Meens J; Pinto N; Ruicci KM; Khan MI; Han MW; Shaikh M; Yoo J; Fung K; MacNeil D; Palma DA; Winquist E; Howlett CJ; Mymryk JS; Ailles L; Boutros PC; Barrett JW; Nichols AC
Oral Oncol; 2020 Feb; 101():104529. PubMed ID: 31864959
[TBL] [Abstract][Full Text] [Related]
35. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
[TBL] [Abstract][Full Text] [Related]
36. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling.
Han Y; Wu Z; Wu T; Huang Y; Cheng Z; Li X; Sun T; Xie X; Zhou Y; Du Z
Cell Death Dis; 2016 Mar; 7(3):e2123. PubMed ID: 26938295
[TBL] [Abstract][Full Text] [Related]
37. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression.
Dauphinot L; De Oliveira C; Melot T; Sevenet N; Thomas V; Weissman BE; Delattre O
Oncogene; 2001 May; 20(25):3258-65. PubMed ID: 11423975
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
[TBL] [Abstract][Full Text] [Related]
40. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth.
Carrillo J; García-Aragoncillo E; Azorín D; Agra N; Sastre A; González-Mediero I; García-Miguel P; Pestaña A; Gallego S; Segura D; Alonso J
Clin Cancer Res; 2007 Apr; 13(8):2429-40. PubMed ID: 17438102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
